8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 13, 2026·SEC
Material company update
Jan 28, 2026·SEC
CONMED Corporation(CNMD)Earnings, Financials & Key Ratios
CNMD•NYSE
21.6× P/E·Price updated Jun 19, 2026
AboutCONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.Show more
- Revenue$1.37B+5.2%
- EBITDA$193M-28.9%
- Net Income$47M-64.5%
- EPS (Diluted)1.51-64.6%
- Gross Margin52.77%-5.9%
- EBITDA Margin14.08%-32.4%
- Operating Margin10.27%-33.0%
- Net Margin3.42%-66.2%
- ROE4.72%-68.0%
CNMD Key Insights
CONMED Corporation (CNMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 37.7%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 2.4%
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CNMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CNMD Price & Volume
CONMED Corporation (CNMD) stock price & volume — 10-year historical chart
Loading chart...
CNMD Growth Metrics
CONMED Corporation (CNMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.69%
5 Years9.77%
3 Years9.55%
TTM4.41%
Profit CAGR
10 Years4.43%
5 Years37.66%
3 Years-
TTM-53.81%
EPS CAGR
10 Years3.31%
5 Years36.38%
3 Years-
TTM-53.37%
Return on Capital
10 Years5.57%
5 Years6.79%
3 Years7.67%
Last Year6.99%
CNMD Recent Earnings
CONMED Corporation (CNMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.89+8.5%
$0.82
Rev
$317M+2.1%
$311M
Q1 2026
Jan 28, 2026Metric
Actual
Est
EPS
$1.43+8.3%
$1.32
Rev
$373M+1.7%
$367M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.08+2.9%
$1.05
Rev
$338M-7.9%
$367M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$1.15+1.8%
$1.13
Rev
$342M+2.3%
$335M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.89vs $0.82+8.5% | $317Mvs $311M+2.1% |
| Q1 2026 | Jan 28, 2026 | $1.43vs $1.32+8.3% | $373Mvs $367M+1.7% |
| Q4 2025 | Nov 5, 2025 | $1.08vs $1.05+2.9% | $338Mvs $367M-7.9% |
| Q3 2025 | Jul 30, 2025 | $1.15vs $1.13+1.8% | $342Mvs $335M+2.3% |
Based on last 12 quarters of dataView full earnings history →
CNMD Peer Comparison
CONMED Corporation (CNMD) competitors in Surgical tools, endoscopy, and robotics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 LMAT | 2.14B | 93.95 | 37.28 | 13.53% | 24.35% | 16.19% | 0.47 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ZBH | 17.22B | 87.97 | 24.78 | 7.2% | 9.05% | 5.77% | 0.59 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 |
Compare CNMD vs Peers
CONMED Corporation (CNMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CNMD Income Statement
CONMED Corporation (CNMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 796.39M | 859.63M | 955.1M | 862.46M | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B | 1.37B |
Revenue Growth % | 4.31% | 7.94% | 11.11% | -9.7% | 17.18% | 3.45% | 19.06% | 5% | 5.16% | 4.41% |
Cost of Goods Sold | 365.35M | 390.52M | 430.38M | 402.16M | 442.6M | 474.23M | 568.5M | 573.98M | 649.12M | 636.88M |
COGS % of Revenue | 45.88% | 45.43% | 45.06% | 46.63% | 43.79% | 45.36% | 45.67% | 43.92% | 47.23% | - |
Gross Profit | 431.04M▲ 0% | 469.11M▲ 8.8% | 524.72M▲ 11.9% | 460.3M▼ 12.3% | 568.04M▲ 23.4% | 571.25M▲ 0.6% | 676.25M▲ 18.4% | 733.03M▲ 8.4% | 725.38M▼ 1.0% | 735.25M▲ 0% |
Gross Margin % | 54.12% | 54.57% | 54.94% | 53.37% | 56.21% | 54.64% | 54.33% | 56.08% | 52.77% | 53.58% |
Gross Profit Growth % | 5.56% | 8.83% | 11.85% | -12.28% | 23.41% | 0.56% | 18.38% | 8.4% | -1.04% | - |
Operating Expenses | 384.11M | 397.81M | 445.6M | 414.29M | 458.32M | 501.19M | 555.64M | 532.71M | 584.24M | 581.85M |
OpEx % of Revenue | 48.23% | 46.28% | 46.66% | 48.04% | 45.35% | 47.94% | 44.64% | 40.76% | 42.51% | - |
Selling, General & Admin | 351.8M | 355.62M | 400.14M | 373.82M | 414.75M | 454.04M | 503.04M | 478.28M | 528.36M | 522.43M |
SG&A % of Revenue | 44.17% | 41.37% | 41.9% | 43.34% | 41.04% | 43.43% | 40.41% | 36.59% | 38.44% | - |
Research & Development | 32.31M | 42.19M | 45.46M | 40.47M | 43.56M | 47.15M | 52.6M | 54.43M | 55.88M | 59.27M |
R&D % of Revenue | 4.06% | 4.91% | 4.76% | 4.69% | 4.31% | 4.51% | 4.23% | 4.16% | 4.07% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 148K |
Operating Income | 46.94M▲ 0% | 71.31M▲ 51.9% | 79.11M▲ 11.0% | 46.01M▼ 41.8% | 109.72M▲ 138.5% | 70.05M▼ 36.2% | 120.6M▲ 72.2% | 200.33M▲ 66.1% | 141.13M▼ 29.5% | 155.42M▲ 0% |
Operating Margin % | 5.89% | 8.29% | 8.28% | 5.33% | 10.86% | 6.7% | 9.69% | 15.33% | 10.27% | 11.33% |
Operating Income Growth % | 24.58% | 51.92% | 10.95% | -41.84% | 138.46% | -36.15% | 72.16% | 66.1% | -29.55% | - |
EBITDA | 105.48M | 133.11M | 151.44M | 118.64M | 180.46M | 119.81M | 192.48M | 272.18M | 193.47M | 219.35M |
EBITDA Margin % | 13.25% | 15.48% | 15.86% | 13.76% | 17.86% | 11.46% | 15.46% | 20.82% | 14.08% | 15.99% |
EBITDA Growth % | 13.44% | 26.19% | 13.77% | -21.66% | 52.11% | -33.61% | 60.65% | 41.41% | -28.92% | -9.94% |
D&A (Non-Cash Add-back) | 58.55M | 61.8M | 72.32M | 72.63M | 70.74M | 49.76M | 71.87M | 71.86M | 52.34M | 63.93M |
EBIT | 46.94M | 71.31M | 73.93M | 45.66M | 108.59M | -41.96M | 120.6M | 200.33M | 141.13M | 155.42M |
Net Interest Income | -18.2M | -20.65M | -42.7M | -44.05M | -35.48M | -28.91M | -39.77M | -37.3M | -31.09M | -29.86M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 18.2M | 20.65M | 42.7M | 44.05M | 35.48M | 28.91M | 39.77M | 37.3M | 31.09M | 29.86M |
Other Income/Expense | -18.2M | -20.65M | -47.89M | -44.41M | -36.61M | -140.92M | -39.77M | -37.3M | -70.01M | -73.62M |
Pretax Income | 28.73M▲ 0% | 50.65M▲ 76.3% | 31.23M▼ 38.4% | 1.6M▼ 94.9% | 73.11M▲ 4460.5% | -70.86M▼ 196.9% | 80.83M▲ 214.1% | 163.03M▲ 101.7% | 71.12M▼ 56.4% | 81.8M▲ 0% |
Pretax Margin % | 3.61% | 5.89% | 3.27% | 0.19% | 7.23% | -6.78% | 6.49% | 12.47% | 5.17% | 5.96% |
Income Tax | -26.75M | 9.8M | 2.6M | -7.91M | 10.56M | 9.72M | 16.37M | 30.61M | 24.06M | 26.95M |
Effective Tax Rate % | -93.12% | 19.35% | 8.34% | -493.7% | 14.45% | -13.72% | 20.25% | 18.77% | 33.83% | 32.95% |
Net Income | 55.49M▲ 0% | 40.85M▼ 26.4% | 28.62M▼ 29.9% | 9.52M▼ 66.7% | 62.54M▲ 557.2% | -80.58M▼ 228.8% | 64.46M▲ 180.0% | 132.42M▲ 105.4% | 47.05M▼ 64.5% | 54.85M▲ 0% |
Net Margin % | 6.97% | 4.75% | 3% | 1.1% | 6.19% | -7.71% | 5.18% | 10.13% | 3.42% | 4% |
Net Income Growth % | 278.39% | -26.37% | -29.95% | -66.75% | 557.16% | -228.84% | 179.99% | 105.44% | -64.47% | -53.81% |
Net Income (Continuing) | 55.49M | 40.85M | 28.62M | 9.52M | 62.54M | -80.58M | 64.46M | 132.42M | 47.05M | 54.85M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.97▲ 0% | 1.41▼ 28.4% | 0.97▼ 31.2% | 0.32▼ 67.0% | 1.94▲ 506.2% | -2.68▼ 238.1% | 2.04▲ 176.1% | 4.26▲ 108.8% | 1.51▼ 64.6% | 1.79▲ 0% |
EPS Growth % | 278.85% | -28.43% | -31.21% | -67.01% | 506.25% | -238.14% | 176.12% | 108.82% | -64.55% | -53.37% |
EPS (Basic) | 1.99 | 1.45 | 1.01 | 0.33 | 2.14 | -2.68 | 2.10 | 4.29 | 1.52 | - |
Diluted Shares Outstanding | 28.17M | 28.89M | 29.5M | 29.46M | 32.22M | 30.04M | 31.55M | 31.11M | 31.15M | 30.62M |
Basic Shares Outstanding | 27.94M | 28.12M | 28.32M | 28.58M | 29.16M | 30.04M | 30.67M | 30.85M | 31.04M | 30.59M |
Dividend Payout Ratio | 40.2% | 54.93% | 78.97% | 239.76% | 37.18% | - | 38.01% | 18.62% | 52.59% | - |
CNMD Balance Sheet
CONMED Corporation (CNMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 356.78M | 374.35M | 397.36M | 416.65M | 460.12M | 581.23M | 615.65M | 640.01M | 672.86M | 670.59M |
Cash & Short-Term Investments | 32.62M | 17.51M | 25.86M | 27.36M | 20.85M | 28.94M | 24.3M | 24.46M | 40.82M | 35.03M |
Cash Only | 32.62M | 17.51M | 25.86M | 27.36M | 20.85M | 28.94M | 24.3M | 24.46M | 40.82M | 35.03M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 167.04M | 181.55M | 189.1M | 177.15M | 183.88M | 191.34M | 242.28M | 237.73M | 247.83M | 0 |
Days Sales Outstanding | 76.56 | 77.09 | 72.27 | 74.97 | 66.41 | 66.8 | 71.04 | 66.39 | 65.81 | 47.01 |
Inventory | 141.44M | 154.6M | 164.62M | 194.87M | 231.64M | 332.32M | 318.32M | 346.72M | 355.54M | 0 |
Days Inventory Outstanding | 141.3 | 144.49 | 139.61 | 176.86 | 191.03 | 255.78 | 204.38 | 220.48 | 199.92 | 104.11 |
Other Current Assets | 0 | 5.39M | 0 | 0 | 0 | 28.62M | 30.75M | 31.1M | 28.67M | 635.56M |
Total Non-Current Assets | 1B | 994.79M | 1.38B | 1.34B | 1.31B | 1.72B | 1.68B | 1.67B | 1.65B | 1.64B |
Property, Plant & Equipment | 116.23M | 113.25M | 118.88M | 111.41M | 108.86M | 115.61M | 120.72M | 115.79M | 113.33M | 0 |
Fixed Asset Turnover | 6.85x | 7.59x | 8.03x | 7.74x | 9.28x | 9.04x | 10.31x | 11.29x | 12.13x | 23.98x |
Goodwill | 401.95M | 400.44M | 618.04M | 618.44M | 617.53M | 815.43M | 806.84M | 805.36M | 807.01M | 806.86M |
Intangible Assets | 414.94M | 413.19M | 532.8M | 501.54M | 471.05M | 681.8M | 649.48M | 617.66M | 582.05M | 573.8M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 63.33M | 62.75M | 102.35M | 96.79M | 98.8M | 93.88M | 96.11M | 116.36M | 137.19M | 263.69M |
Total Assets | 1.36B▲ 0% | 1.37B▲ 0.8% | 1.78B▲ 29.7% | 1.75B▼ 1.3% | 1.77B▲ 0.8% | 2.3B▲ 30.1% | 2.3B▲ 0.1% | 2.31B▲ 0.3% | 2.33B▲ 0.8% | 2.31B▲ 0% |
Asset Turnover | 0.59x | 0.63x | 0.54x | 0.49x | 0.57x | 0.46x | 0.54x | 0.57x | 0.59x | 0.59x |
Asset Growth % | 2.18% | 0.82% | 29.65% | -1.32% | 0.82% | 30.1% | 0.11% | 0.27% | 0.85% | 3.76% |
Total Current Liabilities | 150M | 160.94M | 188.09M | 190.2M | 196.65M | 296.55M | 310.73M | 278.13M | 315.04M | 292.72M |
Accounts Payable | 42.04M | 53.5M | 55.97M | 53.31M | 58.2M | 73.39M | 88.22M | 102.25M | 93.65M | 0 |
Days Payables Outstanding | 42 | 50 | 47.47 | 48.38 | 47.99 | 56.49 | 56.64 | 65.02 | 52.66 | 43.24 |
Short-Term Debt | 14.7M | 18.34M | 13.25M | 18.41M | 12.25M | 69.75M | 0 | 715K | 712K | 711K |
Deferred Revenue (Current) | 34.26M | 42.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 59M | 46.19M | 111.25M | 110.81M | 126.2M | 153.41M | 144.22M | 175.17M | 220.68M | 292M |
Current Ratio | 2.38x | 2.33x | 2.11x | 2.19x | 2.34x | 1.96x | 1.98x | 2.30x | 2.14x | 2.29x |
Quick Ratio | 1.44x | 1.37x | 1.24x | 1.17x | 1.16x | 0.84x | 0.96x | 1.05x | 1.01x | 2.29x |
Cash Conversion Cycle | 175.85 | 171.58 | 164.41 | 203.45 | 209.45 | 266.09 | 218.78 | 221.85 | 213.08 | 107.88 |
Total Non-Current Liabilities | 576.53M | 545.92M | 876.54M | 852.43M | 783.94M | 1.26B | 1.16B | 1.07B | 977.61M | 1B |
Long-Term Debt | 471.74M | 438.56M | 754.72M | 735.22M | 672.41M | 985.08M | 971.48M | 905.07M | 834.23M | 860.16M |
Capital Lease Obligations | 0 | 0 | 17.59M | 15.15M | 0 | 0 | 11.55M | 0 | 0 | 0 |
Deferred Tax Liabilities | 77.67M | 81.06M | 74.49M | 57.88M | 68.54M | 66.72M | 60.9M | 74.08M | 79.53M | 305.58M |
Other Non-Current Liabilities | 27.11M | 26.3M | 29.75M | 44.19M | 42.99M | 203.69M | 111.13M | 86.29M | 63.85M | 63.02M |
Total Liabilities | 726.53M | 706.87M | 1.06B | 1.04B | 980.58M | 1.55B | 1.47B | 1.34B | 1.29B | 1.3B |
Total Debt | 486.44M | 456.9M | 793.17M | 776.45M | 684.66M | 1.05B | 991.25M | 905.78M | 834.94M | 860.87M |
Net Debt | 453.82M | 439.39M | 767.32M | 749.09M | 663.81M | 1.03B | 966.96M | 881.32M | 794.13M | 825.84M |
Debt / Equity | 0.77x | 0.69x | 1.12x | 1.10x | 0.87x | 1.41x | 1.19x | 0.94x | 0.81x | 0.85x |
Debt / EBITDA | 4.61x | 3.43x | 5.24x | 6.54x | 3.79x | 8.80x | 5.15x | 3.33x | 4.32x | 3.92x |
Net Debt / EBITDA | 4.30x | 3.30x | 5.07x | 6.31x | 3.68x | 8.56x | 5.02x | 3.24x | 4.10x | 3.77x |
Interest Coverage | 2.58x | 3.45x | 1.73x | 1.04x | 3.06x | -1.45x | 3.03x | 5.37x | 4.54x | 5.20x |
Total Equity | 631.43M▲ 0% | 662.27M▲ 4.9% | 710.47M▲ 7.3% | 709.04M▼ 0.2% | 785.43M▲ 10.8% | 745.54M▼ 5.1% | 834.22M▲ 11.9% | 962.68M▲ 15.4% | 1.03B▲ 7.3% | 1.02B▲ 0% |
Equity Growth % | 8.76% | 4.88% | 7.28% | -0.2% | 10.77% | -5.08% | 11.89% | 15.4% | 7.31% | 33.21% |
Book Value per Share | 22.41 | 22.92 | 24.09 | 24.06 | 24.38 | 24.82 | 26.44 | 30.94 | 33.17 | 33.23 |
Total Shareholders' Equity | 631.43M | 662.27M | 710.47M | 709.04M | 785.43M | 745.54M | 834.22M | 962.68M | 1.03B | 1.02B |
Common Stock | 313K | 313K | 313K | 313K | 313K | 313K | 313K | 313K | 313K | 313K |
Retained Earnings | 440.08M | 464.85M | 470.84M | 457.42M | 496.61M | 412.63M | 452.53M | 560.28M | 588.77M | 602.59M |
Treasury Stock | -93.68M | -88.89M | -80.74M | -67.64M | -54.05M | -22.78M | -14.99M | -15.63M | -12.89M | 0 |
Accumulated OCI | -49.08M | -55.74M | -59.28M | -63.68M | -54.2M | -57.86M | -50.17M | -58.86M | -46.3M | -44.69M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CNMD Cash Flow Statement
CONMED Corporation (CNMD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 65.57M | 74.7M | 95.13M | 64.53M | 111.77M | 33.37M | 125.35M | 166.97M | 170.69M | 142.63M |
Operating CF Margin % | 8.23% | 8.69% | 9.96% | 7.48% | 11.06% | 3.19% | 10.07% | 12.77% | 12.42% | - |
Operating CF Growth % | 71.54% | 13.93% | 27.35% | -32.17% | 73.2% | -70.15% | 275.69% | 33.2% | 2.23% | -88.52% |
Net Income | 55.49M | 40.85M | 28.62M | 9.52M | 62.54M | -80.58M | 64.46M | 132.42M | 47.05M | 54.85M |
Depreciation & Amortization | 58.55M | 61.8M | 72.32M | 72.63M | 70.74M | 69.52M | 51.4M | 51.3M | 74.28M | 60.2M |
Stock-Based Compensation | 8.47M | 10.04M | 11.78M | 13.11M | 16.34M | 21.73M | 24.26M | 25.56M | 28.32M | 19.96M |
Deferred Taxes | -40.02M | 2.06M | -6.31M | -14.23M | 3M | -6.04M | 700K | 12.2M | 3.52M | 7.72M |
Other Non-Cash Items | 143.41M | 4.21M | 12.37M | 13.41M | 14.84M | 119.44M | 24.11M | -14.8M | 28.96M | 11.99M |
Working Capital Changes | -16.92M | -44.27M | -23.65M | -29.9M | -55.7M | -90.7M | -39.58M | -39.72M | -11.45M | -12.09M |
Change in Receivables | -13.63M | -17.46M | -13.94M | 13.92M | -9.16M | -5.2M | -47.07M | -1.62M | -2.36M | -2.74M |
Change in Inventory | -3.93M | -15.04M | -117K | -30.4M | -37.81M | -78.56M | 14.07M | -31.63M | -6.73M | -11.53M |
Change in Payables | -286K | 12.11M | 38K | -2.98M | 4.89M | 13.3M | 14.85M | 14.71M | -9.75M | 8.05M |
Cash from Investing | -29.05M | -16.51M | -387.66M | -13.64M | -14.87M | -249.53M | -20.03M | -13.08M | -20.96M | -13.92M |
Capital Expenditures | -12.84M | -16.51M | -20.07M | -13.01M | -14.87M | -21.79M | -19.03M | -13.08M | -19.81M | -18.92M |
CapEx % of Revenue | 1.61% | 1.92% | 2.1% | 1.51% | 1.47% | 2.08% | 1.53% | 1% | 1.44% | 1.38% |
Acquisitions | -16.21M | 0 | -367.6M | -3.85M | 0 | -227.74M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 3.23M | 0 | 0 | -1M | 0 | -1.15M | 5M |
Cash from Financing | -34.88M | -72.27M | 300.88M | -52.06M | -101.55M | 225M | -110.43M | -151M | -135.82M | -129.97M |
Debt Issued (Net) | -12.2M | -29.7M | 362.85M | -29.4M | -81.24M | 362.02M | -88M | -72M | -74.59M | -60M |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -37.02M |
Dividends Paid | -22.31M | -22.44M | -22.6M | -22.82M | -23.26M | -23.96M | -24.5M | -24.65M | -24.75M | -18.57M |
Share Repurchases | 0 | 0 | -30.57M | 0 | 0 | -72M | 0 | 0 | 0 | -37.02M |
Other Financing | -372K | -20.12M | -39.37M | 162K | 2.95M | -113.06M | 2.07M | -54.35M | -36.49M | -14.39M |
Net Change in Cash | 5.19M▲ 0% | -15.11M▼ 390.9% | 8.35M▲ 155.2% | 1.5M▼ 82.0% | -6.51M▼ 533.9% | 8.1M▲ 224.4% | -4.65M▼ 157.4% | 163K▲ 103.5% | 16.36M▲ 9935.6% | -455K▲ 0% |
Free Cash Flow | 52.72M▲ 0% | 58.19M▲ 10.4% | 75.07M▲ 29.0% | 51.52M▼ 31.4% | 96.9M▲ 88.1% | 11.58M▼ 88.1% | 106.32M▲ 818.1% | 153.88M▲ 44.7% | 150.88M▼ 2.0% | 123.71M▲ 0% |
FCF Margin % | 6.62% | 6.77% | 7.86% | 5.97% | 9.59% | 1.11% | 8.54% | 11.77% | 10.98% | 9.02% |
FCF Growth % | 124.65% | 10.37% | 28.99% | -31.37% | 88.1% | -88.05% | 818.1% | 44.74% | -1.95% | -24.82% |
FCF per Share | 1.87 | 2.01 | 2.55 | 1.75 | 3.01 | 0.39 | 3.37 | 4.95 | 4.84 | 4.04 |
FCF Conversion (FCF/Net Income) | 1.18x | 1.83x | 3.32x | 6.78x | 1.79x | -0.41x | 1.94x | 1.26x | 3.63x | 2.26x |
Interest Paid | 16.16M | 19.66M | 27.27M | 30.45M | 21.8M | 26.08M | 33.69M | 32.65M | 25.42M | 0 |
Taxes Paid | 8.87M | 11.05M | 10.58M | 9.12M | 8.56M | 9.07M | 19.88M | 15.22M | 0 | 0 |
CNMD Key Ratios
CONMED Corporation (CNMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 9.16% | 6.32% | 4.17% | 1.34% | 8.37% | -10.53% | 8.16% | 14.74% | 4.72% | 5.4% |
Return on Invested Capital (ROIC) | 3.31% | 4.89% | 4.6% | 2.35% | 5.66% | 3.26% | 5.06% | 8.24% | 5.77% | 6.35% |
Gross Margin | 54.12% | 54.57% | 54.94% | 53.37% | 56.21% | 54.64% | 54.33% | 56.08% | 52.77% | 53.58% |
Net Margin | 6.97% | 4.75% | 3% | 1.1% | 6.19% | -7.71% | 5.18% | 10.13% | 3.42% | 4% |
Debt / Equity | 0.77x | 0.69x | 1.12x | 1.10x | 0.87x | 1.41x | 1.19x | 0.94x | 0.81x | 0.85x |
Interest Coverage | 2.58x | 3.45x | 1.73x | 1.04x | 3.06x | -1.45x | 3.03x | 5.37x | 4.54x | 5.20x |
FCF Conversion | 1.18x | 1.83x | 3.32x | 6.78x | 1.79x | -0.41x | 1.94x | 1.26x | 3.63x | 2.26x |
Revenue Growth | 4.31% | 7.94% | 11.11% | -9.7% | 17.18% | 3.45% | 19.06% | 5% | 5.16% | 4.41% |
Related:CNMD Dividend History·CNMD Revenue History·CNMD Price History·CNMD P/E History·CNMD Financial Ratios·CNMD Institutional Holders
CNMD SEC Filings & Documents
CONMED Corporation (CNMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
CNMD Frequently Asked Questions
CONMED Corporation (CNMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CONMED Corporation (CNMD) reported $1.37B in revenue for fiscal year 2025. This represents a 992% increase from $125.6M in 1996.
CONMED Corporation (CNMD) grew revenue by 5.2% over the past year. This is steady growth.
Yes, CONMED Corporation (CNMD) is profitable, generating $54.8M in net income for fiscal year 2025 (3.4% net margin).
Dividend & Returns
Yes, CONMED Corporation (CNMD) pays a dividend with a yield of 2.44%. This makes it attractive for income-focused investors.
CONMED Corporation (CNMD) has a return on equity (ROE) of 4.7%. This is below average, suggesting room for improvement.
CONMED Corporation (CNMD) generated $123.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.